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Abstract We recently reported that APOE promoter activity is
stimulated by cAMP, this effect being mediated by factor AP-2
[Garc|Ła et al. (1996) J. Neurosci. 16, 7550^7556]. Here, we study
whether cAMP-induced phosphorylation modulates the activity
of AP-2. Recombinant AP-2 was phosphorylated in vitro by
protein kinase A (PKA) at Ser239. Mutation of Ser239 to Ala
abolished in vitro phosphorylation of AP-2 by PKA, but not the
DNA binding activity of AP-2. Cotransfection studies showed
that PKA stimulated the effect of AP-2 on the APOE promoter,
but not that of the S239A mutant. Therefore, cAMP may
modulate AP-2 activity by PKA-induced phosphorylation of this
factor.
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1. Introduction
AP-2 is a transcription factor which binds as a dimer to the
palindromic recognition sequence 5P-GCCNNNGGC-3P [1,2],
although several AP-2 binding sites have been encountered
which deviate from this consensus sequence. AP-2 is expressed
in neurons and astrocytes, and it has been suggested to play a
role in the development of the neuronal and astrocytic cell
lineages as well as in the cAMP-dependent activation of as-
trocytes [3^5]. Expression of AP-2 has been shown to be
under the control of cAMP in neuroectodermal cells [5], but
this e¡ect seems to be cell-type speci¢c, since cAMP failed to
induce AP-2 in P19 cells [5], and cAMP did not enhance AP-2
expression in HeLa TK cells [3], in 3T3 ¢broblasts, or in
human glioblastoma cells, all of which show basal AP-2
mRNA [5]. AP-2 has been described to be phosphorylated
both in vitro and in vivo by cAMP-dependent protein kinase
A (PKA) [6] ; however, it is currently unknown whether direct
PKA-induced phosphorylation of AP-2 may mediate the
physiological modulation of AP-2 by cAMP.
We have recently described the presence of allelic polymor-
phisms in the transcriptional regulatory region of apolipopro-
tein E (apoE: protein; APOE : gene) [7], a major plasma lip-
oprotein which in the nervous system is involved in nerve
regeneration [8^10] and in the pathogenesis of Alzheimer’s
disease (AD) [11,12]. These polymorphisms produce varia-
tions in the transcriptional activity of the gene, probably
through di¡erential binding of nuclear proteins [7] ; two of
these common variants are associated with an increase in risk
for developing late-onset AD [13,14]. We have found that the
activity of the proximal APOE promoter is upregulated by
cAMP and retinoic acid, in astrocytic but not hepatic cells
[15]. This regulatory process is mediated by interaction of
factor AP-2 with two sites located in the proximal region
[15]. Studying the stimulatory e¡ect of AP-2 on APOE pro-
moter in hepatic cells, in this report we investigate whether
PKA-induced phosphorylation of AP-2 modulates the activity
of this transcription factor.
2. Materials and methods
2.1. Plasmid constructions and site-directed mutagenesis
For the expression of recombinant AP-2 transcription factor with a
poly-histidine extension at its N-terminal end (AP-2r), an AP-2 ex-
pression vector (kindly provided by Dr. Buettner) was digested with
BamHI and HindIII to isolate a fragment containing the coding re-
gion of the last 315 amino acids of the protein, which was then
subcloned at the corresponding sites in pTrcHisB (Invitrogen Corpo-
ration). Site-directed mutagenesis was performed using the Quick-
change site mutagenesis system kit from Stratagene, following the
manufacturer’s instructions. The AP-2 plasmid was used as template
and the oligonucleotide 5P-GTGCAGCGGCGGCTCGCACCACCC-
GAGTGT-3P and its complement were used as primers; this approach
generated a Ser to Ala substitution at position 239 by exchanging the
underlined nucleotide (AP-2S239A). All the synthetic oligonucleotides
were obtained from Isogen Bioscience (Maarssen, The Netherlands).
The introduced mutation was con¢rmed by DNA sequencing. The
vector for the expression of recombinant AP-2 containing the Ala
to Ser substitution at position 239 (AP-2rS239A) was prepared from
the AP-2S239A vector following the same procedure.
2.2. Expression and protein puri¢cation
Escherichia coli DH5K cultures expressing either AP-2r or AP-
2rS239A were grown at 37‡C in 1 l Luria broth medium containing
50 Wg/ml ampicillin, until an A600 of 0.5^0.6 was reached. After in-
duction with 1 mM isopropyl-L-thiogalactopyranoside for 4 h, cells
were harvested by centrifugation at 6000Ug for 10 min at 4‡C. After
removal of the supernatant, cells were resuspended in 2.6 ml of 40 mM
Tris-HCl, pH 7.6, containing 25% sucrose, 0.2 mM EDTA and 1 mM
phenylmethylsulfonyl £uoride (PMSF), and treated at 4‡C for 60 min
with lysozyme (1 mg/ml). The extract was then denatured by adding
urea to 4 M ¢nal concentration, and incubating at 4‡C for 60 min.
The denatured extract obtained was centrifuged at 63 000Ug for 60
min at 4‡C. The supernatant was dialyzed against 20 mM Tris-HCl,
pH 7.6 containing 1 M urea, 50 mM KCl, 10 mM MgCl2, 1 mM
EDTA, 20% glycerol, 1 mM DTT and 1 mM PMSF for 2 h at 4‡C.
The dialysate was again dialyzed against 50 mM sodium phosphate,
pH 7.8 containing 0.3 M NaCl overnight at 4‡C. The dialysate was
loaded onto a 1 ml Ni2-nitrilotriacetic acid-agarose column (Invitro-
gen Corporation) equilibrated in the last dialysis bu¡er. The column
was washed consecutively with 0.5 M NaCl, 50 mM imidazole, 50 mM
sodium phosphate, pH 6, and 0.5 M NaCl, 100 mM imidazole, 50 mM
sodium phosphate, pH 6. The recombinant fusion proteins were then
eluted with 0.5 M NaCl, 500 mM imidazole, 50 mM sodium phos-
phate, pH 6.0. Fractions of 250 Wl were collected and small aliquots
were used for SDS-PAGE analysis.
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2.3. Phosphorylation assay
Phosphorylation assays were carried out as follows: in a total vol-
ume of 25 Wl, 1 Wg of puri¢ed AP-2r or AP-2rS239A was incubated with
0.1 mM [Q-32P]ATP (2200 cpm/pmol) in 25 mM Tris-HCl, pH 7.6,
5 mM magnesium acetate and 0.01 mM ATP in the presence of four
units of PKA (Sigma) for 15 min at 30‡C. For competition assays, 0.2
Wg/ml or 0.5 Wg/ml peptide substrate for PKA (Kemptide, Sigma) was
preincubated with PKA in the absence of ATP for 5 min at 30‡C.
Casein was used as positive control of PKA phosphorylation (not
shown). Reactions were terminated by adding SDS-denaturing bu¡er.
Labeled proteins were analyzed by 10% SDS-PAGE, and the gel was
dried and exposed to Kodak X-Omat S ¢lm using a Ilford intensifying
screen.
2.4. Electrophoretic mobility shift assay (EMSA)
EMSA assays were carried out as previously reported [13] with
minor modi¢cations. Brie£y, 30 ng of AP-2r puri¢ed protein was
incubated with 50 000 cpm of di¡erent probes in bu¡er A (10 mM
Tris-HCl, pH 7.6, 30 mM KCl, 5% glycerol, 4 mM MgCl2, 1 mM
DTT and 0.5 mM EDTA) for 20 min at room temperature. For
competition assays, AP-2r was preincubated with di¡erent oligonu-
cleotides for 10 min at room temperature. The complexes were sepa-
rated in a 4% non-denaturing polyacrylamide gel, which was dried
and exposed to X-ray ¢lm. The following oligonucleotides were
used: CXX (5P-CTGTGCCTGGGGCAGGGGGAGAACA-3P), m-
117 (5P-CTGTGAAGCTTGAATTCGGAGAACA-3P), NR1 (5P-GC-
TGGTCTCAAACTCCTGAGGTTAA-3P) and NR2 (5P-GCTGGTC-
TCAATCTCCTGAGGTTAA-3P).
2.5. UV crosslinking assay
Puri¢ed AP-2r (30 ng) was incubated with 50 000 cpm of CXX or
m-117 probes in bu¡er A for 20 min at room temperature. The mix-
ture was then crosslinked with 400 mJ/cm2 UV irradiation energy.
Covalent DNA-protein complexes were separated by SDS-PAGE us-
ing a 10% acrylamide gel, which was dried and exposed to X-ray ¢lm.
2.6. Cell culture and transfections
HepG2 cells were grown in DMEM containing 10% fetal bovine
serum. The day before transfection, con£uent cells were subcultured
by trypsinization and 1^3U104 cells per well were plated in 24-well
tissue culture plates. HepG2 cells were transfected by the calcium
phosphate method. Brie£y, calcium phosphate-DNA coprecipitates
were prepared by adding dropwise a 220 mM calcium chloride solu-
tion to an equal volume of vortexing HEPES-bu¡ered saline solution
(280 mM NaCl, 40 mM HEPES, 0.6 mM sodium phosphate, pH 7.05)
containing plasmid. 50 Wl of the DNA precipitates (1.5 Wg each of test
and reference plasmid constructions) was added to each well and
allowed to incubate with the cells for 14 h. Cells were washed once
with serum-free DMEM and replenished with growth medium. Cells
were then harvested on day 2 following transfection. A vector for the
expression of PKA catalytic subunit was a generous gift of Dr. Stan-
ley McKnight.
2.7. Luciferase and L-galactosidase assays
Cells were harvested with 100 Wl of a lysis bu¡er containing 25 mM
Tris-phosphate, 2 mM DTT, 2 mM EDTA, 10% glycerol, 1% Triton
X-100. Unsolubilized material was removed by 2 min centrifugation
and the luciferase and L-galactosidase activities of the extracts were
determined. Luciferase was measured using the Luciferase Assay Sys-
tem (Promega) in a Monolight 2010 luminometer (Analytical Lumi-
nescence Laboratory) by incubation of 40 Wl of cell extract with 90 Wl
of luciferase assay reagent as recommended by the manufacturer. L-
Galactosidase was determined in a 96-well microtiter plate by incu-
bating 20 Wl of cellular extract with 20 Wl of a solution containing 1.4
mg/ml of o-nitrophenyl-L-D-galactopyranoside as described [16]. Ab-
sorbance at 405 nm was determined in a MR 5000 microplate reader
(Dynatech).
2.8. Peptide synthesis, mass spectrometry and protein sequencing
Peptide spanning amino acids 238^254 of AP-2 was synthesized
using standard Fmoc chemistry and phosphorylated at Ser239 by the
global phosphorylation method [17]. The identity of the peptide and
exact location of phosphorylated residue was checked by tandem mass
spectrometry using a nanospray-ion trap mass spectrometer as de-
scribed [18]. Sequencing of AP-2r was performed by in gel digestion
of the protein band by the method of Rosenfeld [19], followed by
peptide separation by RP-HPLC, automatic collection and sequence
analysis of individual peptides by nanospray-ion trap mass spectrom-
etry, as described [18]. An LCQ ion trap mass spectrometer (Finnigan,
ThermoQuest, San Jose CA, USA) was used in this work.
3. Results and discussion
In order to study the e¡ect of PKA on AP-2 activity, a
vector was prepared for the recombinant expression of this
protein in bacteria. Since previous studies described that a
truncated form of bacterially expressed AP-2 lacking the N-
terminal 164 amino acids maintained its ability to bind DNA
in vitro [20], we subcloned a BamHI restriction fragment in a
prokaryotic expression vector to produce polyhistidine-tagged
AP-2 lacking 122 N-terminal residues. This truncated form of
AP-2, designated AP-2r, was expressed with high yields in
bacteria and e⁄ciently puri¢ed using a Ni2 column. SDS-
PAGE analysis of AP-2r preparation yielded a prominent
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Fig. 1. Properties of recombinant AP-2 (AP-2r). A: Analysis by
SDS-PAGE followed by Coomassie staining of the AP-2r prepara-
tion. The protein band corresponding to AP-2r is indicated by an
arrow. B and C: Speci¢c DNA binding activity of AP-2r assayed
by either electrophoretic mobility shift assay (B) or UV-induced
crosslinking followed by SDS-PAGE and autoradiography (C). The
double-stranded, radioactively labeled oligonucleotide probes corre-
sponding to either the consensus sequence of AP-2 binding site
(CXX), the mutated consensus sequence (117) or other non-related
DNA sequences (NR1, NR2) were incubated in the absence (3) or
the presence (+) of AP-2r, which had, in some lanes, previously
been incubated with 50-fold (+) or 100-fold (++) excess unlabeled
oligonucleotide, before being subjected to EMSA or UV-induced
crosslinking. D: In vitro phosphorylation of AP-2r by PKA. AP-2r
was incubated with PKA and [Q-32P]ATP in the absence (3) or the
presence of increasing amounts of kemptide (+ and ++), and sub-
jected to SDS-PAGE analysis followed by autoradiography. The po-
sition of molecular weight markers is shown on the left.
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band of 38 kDa, consistent with its expected molecular weight
(Fig. 1A). The identity of this band was checked by sequenc-
ing of internal peptides by tandem mass spectrometry and by
Western blot analysis using an antibody against C-terminal
end of AP-2 (not shown).
In our previous study by DNase I footprinting analysis, we
found that AP-2 was able to bind the APOE promoter in the
region spanning nucleotides 3107 to 3135 (relative to the
transcriptional start site of the gene) [15]. In that study, we
also found that site-directed mutagenesis at this site in the
APOE promoter (mutant m-117), partially abolished AP-2
stimulation of promoter activity [15]. In order to study the
activity of the recombinant protein, we analyzed the binding
of renatured forms of AP-2r to oligonucleotide probe CXX,
containing nucleotides 3107 to 3135 of APOE promoter, by
electrophoretic mobility shift assays (EMSA). A clear shift
band was observed upon incubation of AP-2r with CXX
probe, which was displaced by excess unlabeled CXX, but
not by other non-related oligonucleotides (NR1 and NR2)
(Fig. 1B). Consistently, AP-2r did not bind oligonucleotide
probe m-117, corresponding to the sequence of the same re-
gion in the promoter mutant (Fig. 1B). These results were
con¢rmed by UV-induced DNA-protein crosslinking assays.
As shown in Fig. 1C, radiolabeled CXX probe covalently
bound AP-2r after UV exposure, this e¡ect being gradually
inhibited by increasing amounts of unlabeled CXX probe, but
not by other unrelated probes. Similarly, radiolabeled m-117
probe was unable to bind AP-2r (Fig. 1C). Taken together,
these results suggested that AP-2r had speci¢c DNA binding
activity.
In order to investigate AP-2 phosphorylation, AP-2r was
incubated with PKA in the presence of [Q-32P]ATP, and the
reaction mixture subjected to SDS-PAGE followed by auto-
radiography. As shown in Fig. 1D, lane 1, AP-2r was phos-
phorylated by PKA. Consistently, this e¡ect was diminished
when PKA was preincubated with kemptide, a speci¢c PKA
peptide substrate (Fig. 1D, lanes 2 and 3). When AP-2r was
phosphorylated by PKA and their DNA binding properties
were analyzed by EMSA, we did not detect any qualitative or
quantitative di¡erence between its behavior and that of non-
phosphorylated AP-2r (not shown), suggesting that PKA
phosphorylation did not alter DNA binding a⁄nity of AP-
2, in agreement with the previous results of Park and Kim [6].
In an attempt to identify the site of phosphorylation of AP-
2r by PKA, the protein was phosphorylated with PKA in the
presence of [Q-32P]ATP, subjected to SDS-PAGE and the ra-
dioactive band digested in-gel with trypsin. The extracted pep-
tides were separated by WRP-HPLC, and radioactivity of the
collected peaks was measured. As shown in Fig. 2, several
peaks of radioactivity were encountered at the beginning of
the gradient, but only a well-de¢ned peak was detected in the
middle of the gradient. Neither automated Edman sequencing
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Fig. 2. Tentative identi¢cation of the site of AP-2r phosphorylation by PKA in vitro. AP-2r was phosphorylated with PKA in the presence of
[Q-32P]ATP and subjected to SDS-PAGE, followed by Coomassie staining; the AP-2r band was then digested in-gel with trypsin. The extracted
tryptic fragments were separated by RP-HPLC and monitored by both UV absorbance and radioactive counting. The arrow indicates the elu-
tion time, in the same column, of synthetic phosphopeptide AP-2(238^254), phosphorylated at Ser239.
Fig. 3. Properties of mutant AP-2rS239A. A: In vitro phosphoryla-
tion by PKA of AP-2r and AP-2rS239A. Identical amounts of both
proteins were incubated with PKA in the presence of [Q-32P]ATP
and subjected to SDS-PAGE, followed by autoradiography. The po-
sition of molecular weigth markers is shown on the left. B: DNA
binding activity. Oligonucleotide probe CXX was incubated alone
(3) or in the presence of either AP-2r or AP-2rS239A, and subjected
to EMSA.
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nor nanospray-quadrupole ion trap analysis of the peptides
present in this peak allowed the detection of any phosphoryl-
ated peptide, probably due to its relatively low concentration.
Since computer analysis predicted the presence of a single
consensus PKA phosphorylation site in AP-2 at Ser239, we
prepared a synthetic peptide, spanning amino acids 238^254
of AP-2 and phosphorylated at Ser239, which corresponded to
the tryptic peptide containing the expected phosphorylation
site. Upon HPLC analysis, this peptide was found to elute
exactly at the same time as the radioactive peak found at
the middle of the gradient (Fig. 2, arrow), giving a ¢rst sug-
gestion that Ser239 could be the site of PKA phosphorylation
of AP-2.
In order to con¢rm this hypothesis, a mutant AP-2 expres-
sion vector was constructed by site-directed mutagenesis, re-
placing Ser by Ala at position 239 in the expression vector
originally used to study the AP-2 e¡ect on APOE promoter
activity [15]. This vector was then used to prepare a bacterial
expression vector to produce the recombinant AP-2 S239A
mutant protein (AP-2rS239A). The identity of the puri¢ed mu-
tant was checked by SDS-PAGE analysis followed by in-gel
digestion with trypsin, WRP-HPLC peptide mapping and mass
spectrometry analysis of several fragments (not shown). When
PKA phosphorylation properties of AP-2r and AP-2rS239A
were directly compared, an almost complete inhibition of
phosphorylation was observed in the case of the mutant pro-
tein (Fig. 3A, compare lanes 1 and 2), thus demonstrating that
Ser239 was the site of phosphorylation of AP-2r by PKA.
In contrast, no di¡erences in the DNA binding properties
could be found between AP-2r and AP-2rS239A by EMSA (Fig.
3B, compare lanes 2 and 3). This result strongly suggested
that Ser239 was not essential for APOE promoter binding
activity of AP-2r.
The physiological relevance of these results was analyzed in
HepG2 cell cultures by measuring the activity of an APOE
promoter-luciferase construct [15]. When cells were cotrans-
fected with either the wild-type or AP-2S239A expression vec-
tor, the stimulation of APOE promoter activity produced by
either vector was indistinguishable (Fig. 4). Therefore, Ser239
in AP-2 was essential neither for DNA binding nor for stim-
ulating APOE promoter activity. In addition, cotransfection
with an expression vector of the PKA catalytic subunit, which
did not appreciably alter the basal APOE promoter activity,
increased by about 50% the stimulatory e¡ect of AP-2 on the
promoter (Fig. 4). Interestingly, this e¡ect was not observed
when AP-2S239A mutant vector was used instead (Fig. 4),
strongly suggesting that the activatory e¡ect of PKA on
AP-2 was mediated through Ser239, i.e. by phosphorylation
of AP-2 at this site.
In conclusion, the results presented in this report indicate
that PKA-induced phosphorylation of AP-2 at Ser239 modu-
lates APOE gene transactivation mediated by AP-2 in HepG2
cells, which were used as a model of AP-2-de¢cient cells. This
mechanism could explain modulation of AP-2 activity by
cAMP in cellular types where cAMP was shown not to mod-
ify AP-2 expression at either the protein or mRNA level.
The basal amounts of PKA holoenzyme in the nucleus is
minimal in cells not exposed to cAMP [21]. As the intracel-
lular concentration of cAMP increases, cAMP binds the PKA
regulatory subunit, producing the dissociation of the catalytic
subunit (PKAc), which translocates to the nucleus [22], where
it phosphorylates several transcription factors. PKAc entry
into the nucleus is relatively slow and constitutes the rate-
limiting step in the transactivation of cAMP-responsive genes.
In recent years several factors have been identi¢ed which need
PKA-mediated phosphorylation at Ser or Thr residues in or-
der to stimulate gene transcription [23^27]. In most cases gene
stimulation produced by these factors is due to a phosphoryl-
ation-mediated modulation of their DNA binding activities
[24,25]. However, PKA-mediated phosphorylation of CREB,
which takes place at Ser133, does not alter its binding to DNA
[28,29]. Our results support the notion that, as in the case of
CREB, phosphorylation of AP-2 at Ser239 does not a¡ect its
DNA binding activity, but rather enhances the activatory
properties of AP-2 by an still unknown mechanism, most
probably modulating binding of AP-2 to other factors. In
this regard, the interactions of AP-2 with other proteins of
the transcription machinery are still poorly understood. Re-
cently, in vivo binding of transcription factor Myc to AP-2
has been described; interaction of Myc was found to take
place through the DNA binding region of AP-2 [30]. An at-
tempt to identify further factors which bind AP-2 is currently
under way in our laboratory.
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